Avidity Biosciences (RNA) News Today $32.10 -1.20 (-3.60%) Closing price 04:00 PM EasternExtended Trading$33.52 +1.43 (+4.44%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Avidity Biosciences (NASDAQ:RNA) Trading 8.5% Higher - Time to Buy?Avidity Biosciences (NASDAQ:RNA) Trading Up 8.5% - Still a Buy?March 25 at 4:20 PM | marketbeat.comCibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Cibc World Markets Corp bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,386 shares of the biotechnology company's stock,March 25 at 3:53 AM | marketbeat.comSwiss National Bank Acquires 18,800 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Swiss National Bank increased its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 174,400 shares of the biotechnology company's stockMarch 25 at 3:35 AM | marketbeat.com198,907 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Raymond James Financial Inc.Raymond James Financial Inc. bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 198,907 shares of the biotechnology company's stock, valuedMarch 25 at 3:20 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $979,632.40 in StockMarch 24 at 4:05 AM | americanbankingnews.comMagnetar Financial LLC Acquires Shares of 22,003 Avidity Biosciences, Inc. (NASDAQ:RNA)Magnetar Financial LLC acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,003 shares of the biotechnology company's stock, valued at aMarch 23 at 5:05 AM | marketbeat.comBrokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Target at $66.69March 23 at 2:09 AM | americanbankingnews.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $246,461.10 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CFO Michael F. Maclean sold 7,935 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $31.06, for a total transaction of $246,461.10. Following the sale, the chief financial officer now directly owns 96,720 shares in the company, valued at $3,004,123.20. The trade was a 7.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 22 at 7:43 PM | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 9,578 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Steven George Hughes sold 9,578 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $31.06, for a total value of $297,492.68. Following the completion of the transaction, the insider now owns 72,850 shares of the company's stock, valued at $2,262,721. The trade was a 11.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 22 at 7:43 PM | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells 31,540 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 31,540 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $31.06, for a total value of $979,632.40. Following the transaction, the chief executive officer now directly owns 305,871 shares in the company, valued at $9,500,353.26. This trade represents a 9.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.March 22 at 7:42 PM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 7,935 SharesMarch 22 at 7:04 AM | insidertrades.comIntech Investment Management LLC Increases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Intech Investment Management LLC raised its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 64.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 60,801 shares of the biotechnology company's stock after acquiring an additional 23,765 shares dMarch 22 at 4:45 AM | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | prnewswire.comProficio Capital Partners LLC Makes New $1.76 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)Proficio Capital Partners LLC acquired a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 60,457 shares of thMarch 20, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7.9% - Time to Sell?Avidity Biosciences (NASDAQ:RNA) Stock Price Down 7.9% - Should You Sell?March 19, 2025 | marketbeat.comScotiabank Reaffirms Their Buy Rating on Avidity Biosciences (RNA)March 19, 2025 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Avidity Biosciences (NASDAQ:RNA)March 19, 2025 | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for Avidity Biosciences (NASDAQ:RNA)March 19, 2025 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Given "Buy" Rating at Chardan CapitalMarch 19, 2025 | americanbankingnews.comAvidity’s del-zota elicits 25% increase in dystrophin in DMD patientsMarch 18, 2025 | msn.com7RNA : Forecasting The Future: 13 Analyst Projections For Avidity...March 18, 2025 | benzinga.comAvidity Biosciences' (RNA) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $60.00 price objective on shares of Avidity Biosciences in a report on Monday.March 18, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $72.00 target price on shares of Avidity Biosciences in a report on Monday.March 18, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Earns Buy Rating from Chardan CapitalChardan Capital reiterated a "buy" rating and set a $65.00 price objective on shares of Avidity Biosciences in a report on Monday.March 18, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Buy" from BrokeragesShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have earned an average recommendation of "Buy" from the thirteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Thirteen analysts have rated the stock with a buy rating. The average twelve-month targetMarch 18, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 38,749 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Charles Schwab Investment Management Inc. increased its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 3.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,028,931 shares of the bioteMarch 18, 2025 | marketbeat.comAvidity Biosciences announces del-zota topline data from EXPLORE44 trialMarch 17, 2025 | markets.businessinsider.comAvidity Biosciences announces ‘positive’ data from Phase 1/2 EXPLORE44 trialMarch 17, 2025 | markets.businessinsider.comAvidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® TrialMarch 17, 2025 | prnewswire.comAvidity Biosciences (NASDAQ:RNA) Now Covered by Analysts at CitigroupMarch 16, 2025 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at BMO Capital MarketsMarch 15, 2025 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Up - Still a Buy?Avidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's WhyMarch 14, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at CitigroupCitigroup began coverage on Avidity Biosciences in a report on Thursday. They issued a "buy" rating and a $70.00 price target on the stock.March 14, 2025 | marketbeat.comCitigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationMarch 14, 2025 | msn.comBank of New York Mellon Corp Buys 59,295 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Bank of New York Mellon Corp increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 19.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 363,017 shares of the biotechnology company's stockMarch 14, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Up 6.2% - What's Next?Avidity Biosciences (NASDAQ:RNA) Stock Price Up 6.2% - Should You Buy?March 13, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at BMO Capital MarketsBMO Capital Markets began coverage on shares of Avidity Biosciences in a report on Wednesday. They issued an "outperform" rating and a $72.00 price objective for the company.March 13, 2025 | marketbeat.comBMO CAPITAL INITIATES AVIDITY BIOSCIENCES WITH OUTPERFORM RATINGMarch 13, 2025 | uk.investing.comAvidity Biosciences initiated with a Buy at CitiMarch 13, 2025 | markets.businessinsider.comBMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform RecommendationMarch 12, 2025 | msn.comAvidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 12, 2025 | prnewswire.comAvidity Biosciences initiated with an Outperform at BMO CapitalMarch 12, 2025 | markets.businessinsider.comAvidity Biosciences (NASDAQ:RNA) Given New $48.00 Price Target at Bank of AmericaBank of America lowered their target price on shares of Avidity Biosciences from $51.00 to $48.00 and set a "buy" rating for the company in a report on Monday.March 11, 2025 | marketbeat.comSteward Partners Investment Advisory LLC Has $1.41 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Steward Partners Investment Advisory LLC reduced its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 48.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owMarch 10, 2025 | marketbeat.comScotiabank Initiates Coverage of Avidity Biosciences (RNA) with Sector Outperform RecommendationMarch 8, 2025 | msn.comAvidity Biosciences (NASDAQ:RNA) Earns Sector Outperform Rating from Analysts at ScotiabankScotiabank started coverage on shares of Avidity Biosciences in a research report on Friday. They issued a "sector outperform" rating and a $70.00 price target on the stock.March 8, 2025 | marketbeat.comCandriam S.C.A. Has $10.49 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Candriam S.C.A. increased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 360,710 shares of the biotechnology company's stock after acquMarch 8, 2025 | marketbeat.com16,270 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Acquired by Aigen Investment Management LPAigen Investment Management LP acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 16,270 shares of the biotechnoloMarch 8, 2025 | marketbeat.comProficio Capital Partners LLC Buys Shares of 60,457 Avidity Biosciences, Inc. (NASDAQ:RNA)Proficio Capital Partners LLC purchased a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 60,457 shMarch 7, 2025 | marketbeat.com13,281 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 13,281 shares of the biotechnology comMarch 4, 2025 | marketbeat.com Remove Ads Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.440.63▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼257▲RNA Articles Average Week Remove Ads Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Intra-Cellular Therapies News Today Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Ascendis Pharma A/S News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
